DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, is reporting on award-winning new research conducted by Sanofi U.S. that indicates the company’s ability to reduce costs through lower utilization of expensive healthcare resources. Sanofi US reported the research at the Academy of Managed Care Pharmacy’s 2023 annual conference Nexus (“AMCP-Nexus”). According to the report, the data shows a 36% reduction in 30-day hospital readmissions for individuals living with type 2 diabetes who used Dario solutions compared to patients living with type 2 diabetes who did not. According to the report, the study evaluated matched Dario users and nonusers with type 2 diabetes to identify the impact of Dario’s digital health solution. The results indicated that Dario users demonstrated less costly use of hospital-related utilization, including a 36% reduction in 30-day hospital readmission rate and 1.6 fewer days in the hospital.

The announcement also noted that a panel of independent judges recognized the research with the AMCP-Nexus Gold ribbon award. The study is part of an ongoing initiative conducted jointly by Dario and Sanofi U.S. “Our research collaboration with Sanofi U.S. continues to yield strong results demonstrating the real, measurable value of digital health for payers,” said Dario chief medical officer Omar Manejwala in the press release. “Helping people improve their self-care of diabetes to such a significant degree that we see a 36% reduction in 30-day hospital readmissions is an incredible testament to the power of Dario’s highly personalized, consumer-centered digital health solution.”

To view the full press release, visit https://ibn.fm/0Snmn

About DarioHealth Corp.

DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN